Shi et al. [21] found that, in glioma, METTL3 promotes drug resistance to temozolomide (TMZ) by increasing the dependence of O6-methylguanine (O6-MeG)-DNA methyltransferase (MGMT) and ANPG on m6A. The gene discussed is METTL3; the disease is central nervous system cancer.